High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of higher
doses of lopinavir/ritonavir, in combination with other anti-HIV medications when
administered as either the capsule or liquid formulations, among patients who have not had
full viral suppression despite treatment with 3 classes of HIV medications, and at least 2
prior courses of treatment with HIV protease inhibitors. In addition, pharmacokinetics of the
active agents, lopinavir and ritonavir will be measured following administration of both the
liquid and capsule formulations and compared.
Phase:
N/A
Details
Lead Sponsor:
Lampiris, Harry W., M.D.
Collaborator:
Abbott
Treatments:
HIV Protease Inhibitors Lopinavir Protease Inhibitors Ritonavir